AR112683A1 - Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende - Google Patents

Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende

Info

Publication number
AR112683A1
AR112683A1 ARP180102329A AR112683A1 AR 112683 A1 AR112683 A1 AR 112683A1 AR P180102329 A ARP180102329 A AR P180102329A AR 112683 A1 AR112683 A1 AR 112683A1
Authority
AR
Argentina
Prior art keywords
levodopa
around
pharmaceutical composition
addition salt
crystal form
Prior art date
Application number
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of AR112683A1 publication Critical patent/AR112683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una base libre de amida de levodopa cristalina y un proceso para elaborarla. En particular, una base libre de amida de levodopa cristalina sustancialmente pura, adecuada para la preparación de composiciones farmacéuticas para el tratamiento de enfermedades o trastornos caracterizados por la neurodegeneración y/o niveles reducidos de dopamina cerebral, tales como la enfermedad de Parkinson. Reivindicación 1: Una forma cristalina de base libre de L-dopamida, en donde la forma cristalina se caracteriza por un patrón de difracción de rayos X de polvo que tiene picos característicos en grados 2q a alrededor de 19,7 y alrededor de 21,0. Reivindicación 2: La forma cristalina de acuerdo con la reivindicación 1 también puede tener picos característicos en grados 2q a alrededor de 18,1 y alrededor de 28,9.
ARP180102329 2017-08-21 2018-08-15 Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende AR112683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762548111P 2017-08-21 2017-08-21

Publications (1)

Publication Number Publication Date
AR112683A1 true AR112683A1 (es) 2019-11-27

Family

ID=63683238

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102329 AR112683A1 (es) 2017-08-21 2018-08-15 Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende

Country Status (2)

Country Link
AR (1) AR112683A1 (es)
WO (1) WO2019038639A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
BR112018010564A2 (pt) 2015-11-24 2018-11-21 Neuroderm Ltd. composições farmacêuticas compreendendo levodopa amida e usos das mesmas

Also Published As

Publication number Publication date
WO2019038639A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AR112683A1 (es) Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
CO2018009889A2 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
WO2017090039A3 (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
AU2015375259A8 (en) Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
PE20210157A1 (es) Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
CO2019007670A2 (es) Un derivado de oxazina base libre en forma cristalina
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure